About Us
We’re insourcing from and bringing world-class scientists, operators, and drug developers to Houston, Texas with seasoned executives and consultants in key functional areas.
Menu
Texas Medical Center Innovation
2450 Holcombe Blvd., Suite X
Houston, TX 77021
Dr. Michael Jason Torres serves as the CEO of CrossBridge Bio, an innovative oncology startup spearheading the advancement of Antibody-Drug Conjugates (ADCs) to redefine cancer treatment paradigms. His entrepreneurial journey began as an Entrepreneur-In-Residence at Texas Medical Center Innovation, where he played a pivotal role in nurturing startups, facilitating their transition from ideation to operational success. Dr. Torres co-founded ReCode Therapeutics, where his leadership as a Co-Founder, Board Member, and VP of R&D propelled an academic endeavor into a robust, venture capital-backed biotech company. His strategic foresight secured a significant $3.2M Award from the CF Foundation and fostered strategic partnerships, showcasing his prowess in business development.
With a Ph.D. in cancer biology earned under the mentorship of Dr. Michael White at UT-Southwestern Medical Center, Dr. Torres boasts a robust academic foundation. His research contributions yielded numerous publications and presentations at prestigious symposia, demonstrating his commitment to advancing scientific knowledge. Furthermore, his postdoctoral research focused on decoding nonsense mutations in diseases like Cystic Fibrosis, reflecting his dedication to unraveling complex genomic illnesses. At CrossBridge Bio, Dr. Torres amalgamates his multifaceted expertise, academic excellence, and entrepreneurial spirit to lead groundbreaking research aimed at developing transformative ADCs, envisioning a future where innovative therapies alleviate the burdens of cancer and offer new avenues of hope to patients worldwide.
Abhishake Chhibber brings over 18 years of extensive experience in the biopharmaceutical industry. This was garnered from several distinguished roles at MedImmune, AstraZeneca, and BioNTech across Finance, Strategy, Portfolio Management and Corporate Development. Notably, he played a pivotal role in building key capabilities in the strategic planning function in the Oncology Business Unit at AstraZeneca and served as the Chief Financial Officer for the Oncology Therapeutic Area at AstraZeneca.
During his tenure at BioNTech, Abhishake Chhibber focused on building the company’s strategic capabilities and driving their growth strategy. His responsibilities encompassed spearheading critical functions such as Corporate Strategy, Strategic Planning and Portfolio Management. His expertise and strategic insights have been pivotal in shaping and enhancing the company’s mid-term & long-term corporate strategy. Abhishake holds a B.S. in Biology and M.B.A from Salisbury University.
Kyoji brings a wealth of expertise and skills in organic chemistry, chemical biology, and medicinal chemistry, pivotal for successful project execution. With a career spanning diverse domains, he has honed skills in organic synthesis, proteomic analysis, chemical protein engineering, and preclinical drug development. His journey started with graduate studies in organic chemistry, followed by postdoctoral work bridging chemistry and biology to unravel biomolecular mechanisms in bacterial physiology and identify therapeutic targets using chemical probe-based proteomic profiling.
Since 2014, as a Principal Investigator at UTHealth Houston, Kyoji has led groundbreaking medicinal chemistry projects focused on pioneering novel antibody-drug conjugates (ADCs). These initiatives have received substantial support from prestigious bodies like NIH/NCI R01, NIH/NIGMS R35, and DOD, underscoring the impact and quality of our research. Additionally, his role as Co-Investigator overseeing ADC production in the CPRIT-funded Cancer Antibody Drug Modalities Core Facility underscores his commitment to advancing therapeutic innovation.
Kyoji’s contributions have been recognized globally, evident through accolades like the 2021 Outstanding Academic Investigator Award from the World ADC San Diego, a testament to our lab’s forefront position in ADC research. Notably, his research, published in esteemed journals, has garnered acclaim, including the Best Preclinical Publication Award from the World ADC San Diego for our pioneering work on dual-drug ADCs. Training the next generation of researchers is also a priority, having mentored seven postdocs, two of whom secured the prestigious fellowship provided by the Japan Society for the Promotion of Science.
